Status: Not yet recruiting
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy. Despite the promising efficacy and safety shown in the phase III clinical trial, real-world data is needed to further support clinical decisions for this patient group. This study aims to evaluate the effectiveness and safety of xeligekimab in real-world clinical settings for adults with moderate to severe plaque psoriasis.
Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Chongqing Genrix Biopharmaceutical Co., LtdUpdated: Jan 31, 2025Locations: 1
Eligibility criteria
Patients 18 years of age or older; [+3]
Patients with drug-induced psoriasis (such as new-onset or exacerbated psoriasis... [+4]